EditorialResearch-agenda bias
References (9)
- et al.
Evidence-based medicine: achievements and prospects
J Clin Epidemiol
(2017) - et al.
Relation between agendas of the research community and the research consumer
Lancet
(2000) - et al.
Evidence in agenda setting: new directions for the Cochrane Collaboration
J Clin Epidemiol
(2013) - et al.
How to increase value and reduce waste when research priorities are set
Lancet
(2014)
There are more references available in the full text version of this article.
Cited by (4)
Describing deprescribing trials better: an elaboration of the CONSORT statement
2020, Journal of Clinical EpidemiologyCitation Excerpt :Public and private resources for funding deprescribing studies should be substantially extended. Deprescribing studies are currently scarce, which is in huge contrast with the growing acknowledgment of polypharmacy and medication overload and its impact on patients and society [50]. The research agenda is clearly biased as sponsors of trials studying the effects of new medication are generally not interested in studying the effects of deprescribing that same medication.
Is there a difference between applicability and generalisability?
2020, Journal of Clinical EpidemiologyPriorities for rheumatic and musculoskeletal disease research in Ireland
2022, BMC RheumatologyResearch-agenda bias: Letters to the editor
2018, Tehran University Medical Journal
© 2018 Elsevier Inc. All rights reserved.